Company news

Regenxbio Inc. news in 2026

Regenxbio Inc.'s news releases, calls and decks from 2026, newest first.

View company

REGENXBIO Reports Third Quarter 2026 Financial Results and Operational Highlights

November 5, 2026

REGENXBIO to Participate in Stifel 2026 Healthcare Conference

November 3, 2026

REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights

October 29, 2026

REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20

October 12, 2026

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

September 24, 2026

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

August 25, 2026

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

August 24, 2026

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

August 6, 2026

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

August 3, 2026

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

July 18, 2026

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

July 17, 2026

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

June 29, 2026

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026

June 24, 2026

REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II

June 22, 2026

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

May 13, 2026

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

May 7, 2026

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

May 6, 2026

REGENXBIO reports new positive interim data from Phase I/II affinity Duchenne® trial of RGX-202

March 10, 2026

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

March 4, 2026

REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

March 4, 2026

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

February 25, 2026

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

February 9, 2026

REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

January 28, 2026

REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

January 10, 2026

Calls in 2026

Decks in 2026